Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Overview of attention for article published in BMC Cancer, December 2018

Altmetric Badge

Mentioned by

twitter: 1 tweeter

reddit: 1 Redditor

Citations

dimensions_citation: 18 Dimensions

Readers on

mendeley: 25 Mendeley

Summary Twitter Reddit Dimensions citations

So far, Dimensions has found 18 publications that cite this research output.

18

The most recent citing publications are shown below. View all 18 publications that cite this research output on Dimensions.

Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance

Article in Translational Lung Cancer Research (April 2023)

The Efficacy and Safety of Afatinib in Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Meta-Analysis

Article in Journal of Oncology (March 2023)

CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations

Article in Frontiers in Oncology (February 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.